Short-term cures without heed to ethics have long-term side effects
Outlook Ethics professors in the world's business schools traditionally play second fiddle to the harder-nosed management science wonks. Somewhere down among the blackboard wipers in the academic pecking order.
But surely these unsung heroes deserve to be promoted this week, given how the pharmaceuticals industry has thrown up such wonderful examples of the damage short-term profit-think does when ethics and social considerations are left behind.
The cudgelling Pfizer has had from scientists, MPs and the media over its bid for AstraZeneca has been almost entirely based on its ruthless cost-cutting, plant closures and reductions in R&D spend. Suddenly, the company's closure of its plant in Sandwich doesn't look so clever. It may have saved a few million dollars – but if the political row it has now created proves fatal for the Astra bid, how many billions of dollars of US tax avoidance will it cost Pfizer in the long term? On a personal level, if he fails to pull off this deal, it could even cost Ian Read his job.
Meanwhile, GlaxoSmithKline's quick-buck enthusiasm for grabbing a share of China has returned to bite it where it hurts, too. We will have to see how Mark Reilly, GSK's former China head, fares through the country's legal system – he may well, of course, be innocent of all wrongdoing.
But serious financial damage by the scandal has already been done. GSK, which has admitted some senior members of staff have broken the law in China, has lost millions. Revenues from China in the third quarter of last year alone were down 61 per cent as doctors opted to prescribe rival manufacturers' versions of its medicines.
And that's before we even begin to count the legal costs. China's new charges are bound to attract the renewed attention of those tenacious upholders of the US Foreign Corrupt Practices Act, the Department of Justice and Securities and Exchange Commission, let alone our own – albeit less fearsome – Serious Fraud Office. Fighting these organisations takes a lot of lawyers.
GSK has faced such ethical scrutiny before, of course, paying $3bn (£1.8bn) in fines in the US a couple of years back for, among other serious ethical transgressions, bribing doctors to prescribe its drugs and promoting its antidepressants for use on children and adolescents.
The fines and lost revenues from ethical breaches can be counted in dollars and cents. But the loss of long-term goodwill among potentially important communities – Britain's scientists, in Pfizer's case – can prove even more costly.
- 1 Nigel Farage: Me vs Russell Brand on Question Time – he's got the chest hair but where are his ideas?
- 2 Harry Potter fans can apply to the Hogwarts-inspired College of Wizardry
- 3 Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
- 4 Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
- 5 Orange Wednesdays are no more
Weather bomb in pictures: Storms cuts power for tens of thousands – and snow is on the way
Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
Russell Brand was rendered speechless on Question Time by this man
Fury at Airbus after it hints the super-jumbo may be mothballed
Disgruntled RBS worker writes hilarious open letter to Russell Brand after anti-capitalist publicity stunt leaves him hungry
Nigel Farage defends Kerry Smith 'ch***y' comment: 'If you are going for a Chinese, what do you say you’re going for?'
Nigel Farage's approval rating hits 'record low' as popularity suffers in wake of Ukip sex scandal
Pakistan school attack live: Taliban kill at least 132 children in 'horrifying' massacre
Sony hack: Angelina Jolie branded 'seriously out of her mind' in further embarrassing leaked email saga
Rozanne Duncan: Ukip expels councillor for 'jaw-dropping' comments made in BBC TV interview
iJobs Money & Business
£20000 - £25000 per annum + OTE £40,000 + Car + Pension: SThree: SThree are a ...
£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...
£20000 - £25000 per annum + OTE £35000: SThree: SThree are a global FTSE 250 b...
£20000 - £25000 per annum + OTE £35K - £45K: SThree: SThree Group have been we...